| Literature DB >> 31934591 |
Young-Gun Park1, Donghyun Jee2, Jin-Woo Kwon2.
Abstract
PURPOSE: To determine the characteristics of diabetic macular edema (DME) patients with cotton-wool spots (CWS).Entities:
Mesh:
Substances:
Year: 2019 PMID: 31934591 PMCID: PMC6942820 DOI: 10.1155/2019/8137417
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1A representative patient who had diabetic macular edema with cotton-wool spots (CWS). (a) The baseline fundus photo image shows multiple CWS around fovea. (b) The baseline spectral domain-optical coherence tomography (SD-OCT) image shows focal ellipsoid zone disruption (red arrow).
Demographics and clinical characteristics of DME patients classified with retinal morphology.
| DME without CWS ( | DME with CWS ( |
| |||
|---|---|---|---|---|---|
| Systemic factors | Sex (male : female) | 32 : 27 | 9 : 12 | 0.521 | |
| Age (years) | 57.0 [52.5; 63.5] | 61.0 [55.0; 64.0] | 0.599 | ||
| HbA1C (%) | 7.79 ± 1.13 | 7.21 ± 1.24 | 0.054 | ||
| Hypertension | 23 (38.98%) | 13 (61.91%) | 0.119 | ||
|
| |||||
| OCT findings | Number of HF | 5.0 [3.0; 10.0] | 5.0 [4.0; 10.0] | 0.570 | |
| DME type (DRT : CME) | 35 : 24 | 12 : 9 | 1.000 | ||
| EZ disruption grade | (-) | 39 (66.10%) | 7 (33.33%) | 0.038 | |
| (+) | 20 (33.90%) | 14 (66.67%) | |||
|
| |||||
| Aqueous humor cytokines and growth factors | ICAM-1 (ng/mL) | 0.00 [0.00; 0.00] | 0.36 [0.00; 2.87] | <0.001 | |
| IL-1 | 0.00 [0.00; 0.43] | 0.17 [0.00; 0.17] | 0.591 | ||
| IL-6 (pg/mL) | 7.96 [4.16; 18.64] | 16.32 [4.98; 31.88] | 0.281 | ||
| IL-8 (pg/mL) | 13.65 [9.77; 23.84] | 11.37 [8.16; 24.43] | 0.364 | ||
| IL-10 (pg/mL) | 0.65 [0.19; 1.32] | 0.53 [0.26; 0.93] | 0.700 | ||
| IL-17 (pg/mL) | 1.36 [0.54; 1.96] | 0.54 [0.00; 2.55] | 0.356 | ||
| PlGF (pg/mL) | 2.85 [1.92; 3.97] | 2.85 [2.32; 7.70] | 0.477 | ||
| VEGF (pg/mL) | 48.18 [22.62; 80.33] | 92.73 [59.70; 184.46] | 0.006 | ||
|
| |||||
| Ocular factors | Baseline BCVA (logMAR) | 0.50 [0.30; 1.00] | 0.70 [0.50; 1.00] | 0.053 | |
| BCVA after IVBs (logMAR) | 0.40 [0.20; 0.70] | 0.70 [0.40; 1.00] | 0.006 | ||
| Baseline CST ( | 353.0 [326.5; 419.5] | 391.0 [347.0; 574.0] | 0.054 | ||
| CST after IVBs ( | 314.0 [286.5; 358.5] | 313.0 [272.0; 398.0] | 0.861 | ||
| DMR (NPDR : PDR) | 26 : 33 | 9 : 12 | 1.000 | ||
Values are expressed as mean ± standard deviation or median and interquartile range, as appropriate. DME: diabetic macular edema; CWS: cotton-wool spot; HbA1c: glycated hemoglobin; HF: hyperreflective foci; CME: cystoid macular edema; DRT: diffuse retinal thickening; EZ: ellipsoid zone; ICAM: intercellular adhesion molecule; IL: interleukin; PlGF: placental growth factor; VEGF: vascular endothelial growth factor; BCVA: best-corrected visual acuity; IVB: intravitreal bevacizumab; CST: central subfield thickness; DMR: DM retinopathy; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy.
Figure 2Box and whisker plots for central subfield thickness (CST) and changes in best-corrected visual acuity (BCVA) in patients with diabetic macular edema, with or without cotton-wool spots (CWS), after three consecutive monthly intravitreal bevacizumab (IVB) injections. The circles represent outliers. (a, b) The CST was significantly reduced after IVB injections in both groups (all, p < 0.001). (c, d) The BCVA improved significantly after IVB injection in the group without CWS, but did not significantly change in the group with CWS (p < 0.001 and p = 0.432, respectively).
Results of logistic regression of the effects of CWS in DME patients.
| Category |
| Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |||
| Sex | Female | 41 (51.25%) | Reference | |||
| Male | 39 (48.75%) | 1.58 (0.58, 4.42) | 0.372 | |||
|
| ||||||
| Age (years) | <60 | 47 (58.75%) | Reference | |||
| ≥60 | 33 (41.25%) | 1.85 (0.68, 5.14) | 0.231 | |||
|
| ||||||
| HbA1c | ≤7 | 23 (28.75%) | Reference | |||
| >7 | 57 (71.25%) | 0.41 (0.14, 1.20) | 0.101 | |||
|
| ||||||
| DMR stage | NPDR | 35 (43.75%) | Reference | |||
| PDR | 45 (56.25%) | 1.05 (0.39, 2.93) | 0.924 | |||
|
| ||||||
| Hypertension | (+) | 36 (45.00%) | Reference | Reference | ||
| (-) | 44 (55.00%) | 2.54 (0.93, 7.34) | 0.074 | 2.34 (0.70, 8.31) | 0.171 | |
|
| ||||||
| ICAM-1 (ng/mL) | <0.36 | 65 (81.25%) | Reference | Reference | ||
| ≥0.36 | 15 (18.75%) | 15.12 (4.29, 64.09) | <0.001 | 13.26 (3.58, 59.16) | <0.001 | |
|
| ||||||
| IL-1 | <0.17 | 46 (57.50%) | Reference | |||
| ≥0.17 | 34 (42.50%) | 1.72 (0.63, 4.77) | 0.289 | |||
|
| ||||||
| IL-6 (pg/mL) | <8.40 | 40 (50.00%) | ||||
| ≥8.40 | 40 (50.00%) | 1.48 (0.54, 4.12) | 0.447 | |||
|
| ||||||
| IL-8 (pg/mL) | <13.14 | 40 (50.00%) | Reference | |||
| ≥13.14 | 40 (50.00%) | 0.68 (0.24, 1.84) | 0.447 | |||
|
| ||||||
| IL-10 (pg/mL) | <0.65 | 36 (45.00%) | Reference | |||
| ≥0.65 | 44 (55.00%) | 0.67 (0.24, 1.82) | 0.430 | |||
|
| ||||||
| IL-17 (pg/mL) | <1.36 | 36 (45.00%) | Reference | |||
| ≥1.36 | 44 (55.00%) | 0.67 (0.24, 1.82) | 0.430 | |||
|
| ||||||
| VEGF (pg/mL) | <59.65 | 40 (50.00%) | Reference | Reference | ||
| ≥59.65 | 40 (50.00%) | 3.40 (1.20, 10.69) | 0.026 | 0.321 (0.95, 12.41) | 0.071 | |
|
| ||||||
| PlGF (pg/mL) | <2.85 | 36 (45.00%) | Reference | |||
| ≥2.85 | 44 (55.00%) | 1.47 (0.54, 4.20) | 0.460 | |||
CWS: cotton-wool spot; DME: diabetic macular edema; OR: odds ratio; CI: confidence interval; ICAM: intercellular adhesion molecule; IL: interleukin; VEGF: vascular endothelial growth factor; PlGF: placental growth factor.